Data from Pharmawand - Curated by EPG Health - Date added 10 February 2018

Salix Pharmaceuticals, Ltd ,a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., and its partner Norgine B.V. have received notice that the FDA has extended the PDUFA action date for its review of the New Drug Application for PLenvu (NER 1006) by three months to 13 May 2018. The PDUFA action date has been extended to allow the FDA more time to review additional data that was recently provided at its request.

Plenvu was licensed by Salix from Norgine in August 2016 for introduction to the U.S. market. Salix and Norgine will continue to work closely with the FDA to support the review of Plenvu, a next-generation bowel cleansing preparation for colonoscopies.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Load more

Related Content